AU2002214590A1 - Protein-protein interactions in neurodegenerative diseases - Google Patents

Protein-protein interactions in neurodegenerative diseases

Info

Publication number
AU2002214590A1
AU2002214590A1 AU2002214590A AU1459002A AU2002214590A1 AU 2002214590 A1 AU2002214590 A1 AU 2002214590A1 AU 2002214590 A AU2002214590 A AU 2002214590A AU 1459002 A AU1459002 A AU 1459002A AU 2002214590 A1 AU2002214590 A1 AU 2002214590A1
Authority
AU
Australia
Prior art keywords
protein
neurodegenerative diseases
interactions
protein interactions
neurodegenerative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002214590A
Inventor
Paul L. Bartel
Karen Heichman
Jean-Marc Roch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Myriad Genetics Inc
Original Assignee
Myriad Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Myriad Genetics Inc filed Critical Myriad Genetics Inc
Publication of AU2002214590A1 publication Critical patent/AU2002214590A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Neurosurgery (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2002214590A 2000-10-17 2001-10-16 Protein-protein interactions in neurodegenerative diseases Abandoned AU2002214590A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24079000P 2000-10-17 2000-10-17
US60/240,790 2000-10-17
PCT/US2001/032197 WO2002033113A2 (en) 2000-10-17 2001-10-16 Protein-protein interactions in neurodegenerative diseases

Publications (1)

Publication Number Publication Date
AU2002214590A1 true AU2002214590A1 (en) 2002-04-29

Family

ID=22907949

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2002213241A Abandoned AU2002213241A1 (en) 2000-10-17 2001-10-16 Protein-protein interactions in neurodegenerative diseases
AU2002213239A Abandoned AU2002213239A1 (en) 2000-10-17 2001-10-16 Protein-protein interactions in neurodegenerative diseases
AU2002214590A Abandoned AU2002214590A1 (en) 2000-10-17 2001-10-16 Protein-protein interactions in neurodegenerative diseases

Family Applications Before (2)

Application Number Title Priority Date Filing Date
AU2002213241A Abandoned AU2002213241A1 (en) 2000-10-17 2001-10-16 Protein-protein interactions in neurodegenerative diseases
AU2002213239A Abandoned AU2002213239A1 (en) 2000-10-17 2001-10-16 Protein-protein interactions in neurodegenerative diseases

Country Status (3)

Country Link
US (7) US20020119155A1 (en)
AU (3) AU2002213241A1 (en)
WO (3) WO2002033113A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040226056A1 (en) * 1998-12-22 2004-11-11 Myriad Genetics, Incorporated Compositions and methods for treating neurological disorders and diseases
WO2003013437A2 (en) * 2001-08-07 2003-02-20 University Of Delaware Compositions and methods for the prevention and treatment of huntington's disease
US20040096880A1 (en) * 2001-08-07 2004-05-20 Kmiec Eric B. Compositions and methods for the treatment of diseases exhibiting protein misassembly and aggregation
WO2003091428A1 (en) * 2002-04-23 2003-11-06 Riken Novel proteins and dnas encoding the same
GB0304993D0 (en) * 2003-03-05 2003-04-09 Univ Nottingham Trent Novel screening method
AU2003298171A1 (en) * 2003-09-05 2005-03-29 Cellzome Ag Protein complexes associated with app-processing
JP2005139164A (en) * 2003-11-10 2005-06-02 Toudai Tlo Ltd Pharmaceutical composition for treating neuropathy and neurodegenerative disease
WO2005095630A2 (en) * 2004-03-02 2005-10-13 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with mitogen-activated protein kinase kinase kinase 10 (map3k10)
GB0420091D0 (en) * 2004-09-10 2004-10-13 Univ Nottingham Trent Medical implant materials
US9265458B2 (en) 2012-12-04 2016-02-23 Sync-Think, Inc. Application of smooth pursuit cognitive testing paradigms to clinical drug development
US9380976B2 (en) 2013-03-11 2016-07-05 Sync-Think, Inc. Optical neuroinformatics
CN104535767B (en) * 2014-12-30 2016-06-22 佛山安普泽生物医药股份有限公司 Monoclonal antibody against EGFR biologic activity detection method
CN111836624A (en) 2018-01-12 2020-10-27 百时美施贵宝公司 Antisense oligonucleotides targeting alpha-synuclein and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7108986B2 (en) * 1998-10-16 2006-09-19 The Regents Of The University Of California Glypican-1 in human breast cancer
EP1234174A1 (en) * 1999-12-02 2002-08-28 Myriad Genetics, Inc. Protein-protein interactions

Also Published As

Publication number Publication date
US20020106773A1 (en) 2002-08-08
WO2002033113A2 (en) 2002-04-25
AU2002213241A1 (en) 2002-04-29
WO2002033114A3 (en) 2003-02-13
US20020115607A1 (en) 2002-08-22
US20020119155A1 (en) 2002-08-29
WO2002033112A3 (en) 2002-08-29
US20020115119A1 (en) 2002-08-22
WO2002033112A2 (en) 2002-04-25
WO2002033114A2 (en) 2002-04-25
US20020119927A1 (en) 2002-08-29
US20030186317A1 (en) 2003-10-02
US20020114799A1 (en) 2002-08-22
AU2002213239A1 (en) 2002-04-29
WO2002033113A3 (en) 2005-12-29

Similar Documents

Publication Publication Date Title
AU2002226072A1 (en) Value-instance-connectivity-computer-implemented database
AU2002230974A1 (en) Day trading system
AU2001240819A1 (en) Proteomics database
AU2002214589A1 (en) Protein-protein interactions in neurodegenerative diseases
AU2002304814A1 (en) Protein-protein interactions in adipocytes
AU2001239975A1 (en) Least choice first arbiter
AU2002223503A1 (en) Decondenser unit
AU2002214590A1 (en) Protein-protein interactions in neurodegenerative diseases
AU1936201A (en) Protein-protein interactions
AU2002227492A1 (en) Transporter
AU2002301358A1 (en) Improvements in Transmissometers
AU2002301354A1 (en) Improvements in Transmissometers
AU2002230895A1 (en) Protein-protein interactions
AU2001252656A1 (en) Material selling system
AU2001284265A1 (en) Genetic study
AU2001268621A1 (en) Protein-protein interactions
AU2002243234A1 (en) Embryogenesis associated proteins
AU2001263325A1 (en) Protein-protein interactions
AU2001238415A1 (en) Gtpase activating proteins
AU2001271843A1 (en) Gtp-binding proteins
AU2002236645A1 (en) Protein-protein interactions
AU2002230728A1 (en) Protein-protein interactions
AU2002249808A1 (en) Protein-protein interactions
AU2001278777A1 (en) Irap-binding protein
AU2001241044A1 (en) Mitf-associated proteins